Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $9.33.

SANA has been the subject of several analyst reports. Bank of America dropped their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $2.79 on Friday. The company’s 50 day moving average price is $3.40 and its two-hundred day moving average price is $3.31. Sana Biotechnology has a 12-month low of $2.61 and a 12-month high of $6.55. The firm has a market cap of $835.21 million, a PE ratio of -3.67 and a beta of 2.18.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, research analysts expect that Sana Biotechnology will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Alphabet Inc. acquired a new position in Sana Biotechnology during the second quarter valued at approximately $9,816,000. Bank of New York Mellon Corp bought a new stake in shares of Sana Biotechnology during the 2nd quarter worth $1,667,000. Bank of America Corp DE acquired a new stake in Sana Biotechnology in the second quarter valued at about $20,062,000. Deutsche Bank AG bought a new position in Sana Biotechnology in the second quarter valued at about $2,251,000. Finally, Canada Pension Plan Investment Board acquired a new position in Sana Biotechnology during the second quarter worth about $35,662,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body.